Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

被引：197

作者：

Jabbari, Ali ^{[1
]}

Dai, Zhenpeng ^{[1
]}

Xing, Luzhou ^{[2
]}

Cerise, Jane E. ^{[1
]}

Ramot, Yuval ^{[3
]}

Berkun, Yackov ^{[4
]}

Sanchez, Gina A. Montealegre ^{[5
]}

Goldbach-Mansky, Raphaela ^{[5
]}

Christiano, Angela M. ^{[1
,6
]}

Clynes, Raphael ^{[1
,2
,7
]}

Zlotogorski, Abraham ^{[3
]}

机构：

[1] Columbia Univ, Dept Dermatol, New York, NY 10032 USA

[2] Columbia Univ, Dept Pathol, New York, NY 10032 USA

[3] Hadassah Hebrew Univ, Med Ctr, Dept Dermatol, Jerusalem, Israel

[4] Hadassah Hebrew Univ, Med Ctr, Dept Pediat, Jerusalem, Israel

[5] NIAMS, Translat Autoinflammatory Dis Sect, NIH, Bethesda, MD USA

[6] Columbia Univ, Dept Genet & Dev, New York, NY USA

[7] Columbia Univ, Dept Med, New York, NY 10032 USA

来源：

EBIOMEDICINE | 2015年 / 2卷 / 04期

关键词：

Alopecia areata; Interferon gamma; JAK inhibitor; CANDLE syndrome; Autoimmune disease; Baricitinib; Gene expression profiling; Autoinflammatory; ATYPICAL NEUTROPHILIC DERMATOSIS; PROTEASOME SUBUNIT; PLAQUE PSORIASIS; LIPODYSTROPHY; TOFACITINIB; UNIVERSALIS; EFFICACY; PATIENT; SAFETY; TRIAL;

D O I：

10.1016/j.ebiom.2015.02.015

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Background: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules. Methods: A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studieswere conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib. Findings: The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment. Interpretation: Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials. (C) 2015 The Authors. Published by Elsevier B.V.

引用

页码：351 / 355

页数：5

共 18 条

[1]

PSMB8 Encoding the β5i Proteasome Subunit Is Mutated in Joint Contractures, Muscle Atrophy, Microcytic Anemia, and Panniculitis-Induced Lipodystrophy Syndrome [J].

Agarwal, Anil K. ;

Xing, Chao ;

DeMartino, George N. ;

Mizrachi, Dario ;

Dolores Hernandez, Maria ;

Sousa, Ana Berta ;

Martinez de Villarreal, Laura ;

dos Santos, Heloisa G. ;

Garg, Abhimanyu .

AMERICAN JOURNAL OF HUMAN GENETICS, 2010, 87 (06) :866-872

[2]

Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome [J].

Arima, Kazuhiko ;

Kinoshita, Akira ;

Mishima, Hiroyuki ;

Kanazawa, Nobuo ;

Kaneko, Takeumi ;

Mizushima, Tsunehiro ;

Ichinose, Kunihiro ;

Nakamura, Hideki ;

Tsujino, Akira ;

Kawakami, Atsushi ;

Matsunaka, Masahiro ;

Kasagi, Shimpei ;

Kawano, Seiji ;

Kumagai, Shunichi ;

Ohmura, Koichiro ;

Mimori, Tsuneyo ;

Hirano, Makito ;

Ueno, Satoshi ;

Tanaka, Keiko ;

Tanaka, Masami ;

Toyoshima, Itaru ;

Sugino, Hirotoshi ;

Yamakawa, Akio ;

Tanaka, Keiji ;

Niikawa, Norio ;

Furukawa, Fukumi ;

Murata, Shigeo ;

Eguchi, Katsumi ;

Ida, Hiroaki ;

Yoshiura, Koh-ichiro .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (36) :14914-14919

[3]

Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci [J].

Betz, Regina C. ;

Petukhova, Lynn ;

Ripke, Stephan ;

Huang, Hailiang ;

Menelaou, Androniki ;

Redler, Silke ;

Becker, Tim ;

Heilmann, Stefanie ;

Yamany, Tarek ;

Duvic, Madeliene ;

Hordinsky, Maria ;

Norris, David ;

Price, Vera H. ;

Mackay-Wiggan, Julian ;

de Jong, Annemieke ;

DeStefano, Gina M. ;

Moebus, Susanne ;

Boehm, Markus ;

Blume-Peytavi, Ulrike ;

Wolff, Hans ;

Lutz, Gerhard ;

Kruse, Roland ;

Bian, Li ;

Amos, Christopher I. ;

Lee, Annette ;

Gregersen, Peter K. ;

Blaumeiser, Bettina ;

Altshuler, David ;

Clynes, Raphael ;

de Bakker, Paul I. W. ;

Noethen, Markus M. ;

Daly, Mark J. ;

Christiano, Angela M. .

NATURE COMMUNICATIONS, 2015, 6

[4]

Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis [J].

Craiglow, Brittany G. ;

King, Brett A. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (12) :2988-2990

[5]

Alopecia areata: Clinical presentation, diagnosis, and unusual cases [J].

Finner, Andreas M. .

DERMATOLOGIC THERAPY, 2011, 24 (03) :348-354

[6]

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].

Fleischmann, Roy ;

Kremer, Joel ;

Cush, John ;

Schulze-Koops, Hendrik ;

Connell, Carol A. ;

Bradley, John D. ;

Gruben, David ;

Wallenstein, Gene V. ;

Zwillich, Samuel H. ;

Kanik, Keith S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507

[7]

Freyschmidt Paul P., 2006, BRIT J DERMATOL, V155, P515

[8]

Genovese M.C, 2012, 24 WEEK RESULTS BLIN, V64, pS1049

[9]

Type 1 interferon signature in the scalp lesions of alopecia areata [J].

Ghoreishi, M. ;

Martinka, M. ;

Dutz, J. P. .

BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (01) :57-62

[10]

Mutations in proteasome subunit ß type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity [J].

Liu, Yin ;

Ramot, Yuval ;

Torrelo, Antonio ;

Paller, Amy S. ;

Si, Nuo ;

Babay, Sofia ;

Kim, Peter W. ;

Sheikh, Afzal ;

Lee, Chyi-Chia Richard ;

Chen, Yongqing ;

Vera, Angel ;

Zhang, Xue ;

Goldbach-Mansky, Raphaela ;

Zlotogorski, Abraham .

ARTHRITIS AND RHEUMATISM, 2012, 64 (03) :895-907

← 1 2 →